Sun Pharmaceutical Industries Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Dilip Shanghvi
Chief executive officer
₹54.5m
Total compensation
| CEO salary percentage | 75.2% |
| CEO tenure | 31.1yrs |
| CEO ownership | 9.6% |
| Management average tenure | 2.3yrs |
| Board average tenure | 2.9yrs |
Recent management updates
Recent updates
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Mar 13
Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Feb 03Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today
Jan 05Getting In Cheap On Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Is Unlikely
Dec 18Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?
Oct 04Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?
Jul 03We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Can Manage Its Debt With Ease
Jun 15Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) A Risky Investment?
Mar 14Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹7.50
Feb 03These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Reasonably Well
Dec 09Does This Valuation Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Imply Investors Are Overpaying?
Oct 13These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Safely
Sep 04Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Aug 05Estimating The Intrinsic Value Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
Jul 12Does Sun Pharmaceutical Industries (NSE:SUNPHARMA) Have A Healthy Balance Sheet?
Jun 02Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?
Apr 28Are Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Investors Paying Above The Intrinsic Value?
Apr 09Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹7.00
Feb 02Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) Using Too Much Debt?
Feb 02Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?
Jan 19Estimating The Intrinsic Value Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
Dec 27Sun Pharmaceutical Industries (NSE:SUNPHARMA) Seems To Use Debt Rather Sparingly
Nov 04Here's Why I Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today
Oct 21Calculating The Intrinsic Value Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
Sep 27CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | ₹89b |
| Sep 30 2023 | n/a | n/a | ₹85b |
| Jun 30 2023 | n/a | n/a | ₹84b |
| Mar 31 2023 | ₹55m | ₹41m | ₹85b |
| Dec 31 2022 | n/a | n/a | ₹42b |
| Sep 30 2022 | n/a | n/a | ₹41b |
| Jun 30 2022 | n/a | n/a | ₹39b |
| Mar 31 2022 | ₹51m | ₹38m | ₹33b |
| Dec 31 2021 | n/a | n/a | ₹64b |
| Sep 30 2021 | n/a | n/a | ₹62b |
| Jun 30 2021 | n/a | n/a | ₹60b |
| Mar 31 2021 | ₹46m | ₹35m | ₹29b |
| Dec 31 2020 | n/a | n/a | ₹24b |
| Sep 30 2020 | n/a | n/a | ₹15b |
| Jun 30 2020 | n/a | n/a | ₹7b |
| Mar 31 2020 | ₹43m | ₹32m | ₹38b |
| Dec 31 2019 | n/a | n/a | ₹40b |
| Sep 30 2019 | n/a | n/a | ₹43b |
| Jun 30 2019 | n/a | n/a | ₹30b |
| Mar 31 2019 | ₹263k | ₹1 | ₹27b |
| Dec 31 2018 | n/a | n/a | ₹34b |
| Sep 30 2018 | n/a | n/a | ₹24b |
| Jun 30 2018 | n/a | n/a | ₹36b |
| Mar 31 2018 | ₹34m | ₹28m | ₹21b |
Compensation vs Market: Dilip's total compensation ($USD654.09K) is below average for companies of similar size in the Indian market ($USD942.67K).
Compensation vs Earnings: Dilip's compensation has been consistent with company performance over the past year.
CEO
Dilip Shanghvi (68 yo)
31.1yrs
Tenure
₹54,534,909
Compensation
Mr. Dilip Shantilal Shanghvi serves as Chairman of Board of Directors of Taro Pharmaceutical Industries Ltd at Taro Pharmaceuticals U.S.A., Inc. He has been the Chairman of Sun Pharma Advanced Research Com...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Executive Director | no data | ₹54.53m | 9.6% ₹ 342.1b | |
| Director of Corporate Development | no data | ₹65.30m | no data | |
| Chief Financial Officer | 6.8yrs | ₹38.89m | no data | |
| Executive Vice-President of Global Operations | no data | no data | no data | |
| EVP & Chief Information Officer | no data | no data | no data | |
| Head of Investor Relations | no data | no data | no data | |
| Company Secretary & Compliance Officer | 2.3yrs | no data | no data | |
| Chief Human Resources Officer | less than a year | no data | no data | |
| Chief Executive Officer of India Business | no data | no data | no data | |
| Executive VP | no data | no data | 0.12% ₹ 4.3b | |
| Chief Executive Officer of North America Business | 7.7yrs | no data | no data | |
| Senior VP - Corporate Relations & CSR - India Regulatory Affairs | no data | no data | no data |
2.3yrs
Average Tenure
59yo
Average Age
Experienced Management: SUNPHARMA's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Executive Director | 31.1yrs | ₹54.53m | 9.6% ₹ 342.1b | |
| Executive VP | less than a year | no data | 0.12% ₹ 4.3b | |
| Non-Executive & Non-Independent Director | 30.3yrs | ₹1.90m | 1.8% ₹ 64.1b | |
| Non-Executive & Independent Director | 2.9yrs | ₹4.80m | no data | |
| Non-Executive Independent Director | 5.9yrs | ₹7.60m | 0.00033% ₹ 11.8m | |
| Independent Director | less than a year | no data | no data | |
| Lead Independent Director | 2.9yrs | ₹8.50m | no data | |
| Independent Director | 1.4yrs | ₹2.17m | no data |
2.9yrs
Average Tenure
66.5yo
Average Age
Experienced Board: SUNPHARMA's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.